bevacizumab + oxaliplatin + pemetrexed

This is a combination regimen consisting of three drugs—bevacizumab, oxaliplatin, and pemetrexed—used primarily in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC). - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis (the formation of new blood vessels) essential for tumor growth. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. - **Pemetrexed** is an antifolate antineoplastic agent that disrupts folate-dependent metabolic processes essential for cell replication. The combination has been studied as both first-line and subsequent therapy in advanced NSCLC, showing promising efficacy with manageable toxicity profiles[1][2][6][8]. The most common toxicities include hypertension, neutropenia, peripheral neuropathy, and fatigue[1][2][6]. This regimen may also be considered for patients with brain metastases from NSCLC due to its tolerability profile[1][4].

Brand names

Avastin + Eloxatin + Alimta

Other names

oxaliplatin pemetrexed bevacizumab combination